Insider Buying: Rallybio (NASDAQ:RLYB) Major Shareholder Purchases $142,596.00 in Stock

Rallybio Corporation (NASDAQ:RLYB) major shareholder Adar1 Capital Management, Llc bought 10,200 shares of the stock in a transaction that occurred on Tuesday, May 19th. The stock was bought at an average price of $13.98 per share, with a total value of $142,596.00. Following the completion of the purchase, the insider directly owned 926,352 shares in the company, valued at $12,950,400.96. This represents a 1.11% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through the SEC website. Major shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.

Adar1 Capital Management, Llc also recently made the following trade(s):

• On Monday, May 18th, Adar1 Capital Management, Llc acquired 6,009 shares of Rallybio stock. The shares were bought at an average price of $13.98 per share, with a total value of $84,005.82.
• On Friday, May 15th, Adar1 Capital Management, Llc acquired 300 shares of Rallybio stock. The shares were bought at an average cost of $13.90 per share, for a total transaction of $4,170.00.
• On Wednesday, May 13th, Adar1 Capital Management, Llc bought 79,259 shares of Rallybio stock. The stock was purchased at an average price of $13.99 per share, with a total value of $1,108,833.41.
• On Tuesday, May 12th, Adar1 Capital Management, Llc purchased 800 shares of Rallybio stock. The shares were purchased at an average cost of $13.83 per share, with a total value of $11,064.00.
• On Monday, May 11th, Adar1 Capital Management, Llc acquired 50,000 shares of Rallybio stock. The stock was purchased at an average cost of $14.00 per share, for a total transaction of $700,000.00.
• On Tuesday, May 5th, Adar1 Capital Management, Llc acquired 35,101 shares of Rallybio stock. The stock was purchased at an average price of $14.00 per share, with a total value of $491,414.00.
• On Monday, May 4th, Adar1 Capital Management, Llc purchased 120,804 shares of Rallybio stock. The stock was acquired at an average price of $13.97 per share, for a total transaction of $1,687,631.88.

Rallybio Trading Up 3.3%

Shares of NASDAQ RLYB opened at $15.88 on Friday. The company has a 50 day simple moving average of $10.28 and a two-hundred day simple moving average of $7.38. The stock has a market cap of $84.16 million, a price-to-earnings ratio of -3.66 and a beta of -1.10. Rallybio Corporation has a 12 month low of $2.16 and a 12 month high of $16.00.

Rallybio (NASDAQ:RLYB) last issued its earnings results on Wednesday, May 13th. The company reported ($1.46) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.20) by ($0.26). The business had revenue of $0.21 million for the quarter, compared to analysts’ expectations of $0.21 million. Rallybio had a negative return on equity of 55.79% and a negative net margin of 911.07%.

Analysts Set New Price Targets

A number of analysts have recently commented on RLYB shares. Wall Street Zen upgraded Rallybio to a “hold” rating in a research note on Saturday, March 28th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Rallybio in a research note on Friday, May 8th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock has an average rating of “Sell”.

Hedge Funds Weigh In On Rallybio

Hedge funds have recently made changes to their positions in the company. Renaissance Technologies LLC boosted its stake in shares of Rallybio by 16.9% in the fourth quarter. Renaissance Technologies LLC now owns 835,692 shares of the company’s stock worth $573,000 after acquiring an additional 120,892 shares during the last quarter. Citadel Advisors LLC grew its holdings in shares of Rallybio by 576.1% during the third quarter. Citadel Advisors LLC now owns 438,705 shares of the company’s stock worth $219,000 after buying an additional 373,821 shares in the last quarter. Geode Capital Management LLC grew its holdings in shares of Rallybio by 1.2% during the fourth quarter. Geode Capital Management LLC now owns 248,005 shares of the company’s stock worth $170,000 after buying an additional 2,996 shares in the last quarter. Susquehanna International Group LLP raised its position in shares of Rallybio by 485.9% in the third quarter. Susquehanna International Group LLP now owns 136,294 shares of the company’s stock valued at $68,000 after buying an additional 113,031 shares during the last quarter. Finally, XTX Topco Ltd raised its position in shares of Rallybio by 64.6% in the fourth quarter. XTX Topco Ltd now owns 97,313 shares of the company’s stock valued at $67,000 after buying an additional 38,205 shares during the last quarter. Institutional investors and hedge funds own 90.34% of the company’s stock.

About Rallybio

Rallybio Therapeutics, Inc (NASDAQ: RLYB) is a clinical‐stage biotechnology company focused on developing and commercializing therapies for people living with rare genetic diseases. The company’s scientific approach leverages diverse modalities—including monoclonal antibodies, small molecules and enzyme replacement—to address high‐unmet‐need conditions in areas such as immunodeficiency, metabolic disorders and dermatologic diseases. Rallybio’s pipeline is designed to advance through registrational clinical trials with the goal of delivering first‐in‐class or best‐in‐class therapies to patients who currently have limited or no approved treatment options.

Among Rallybio’s lead programs is RBX‐100, an investigational therapy for congenital athymia, a rare pediatric immunodeficiency.